MediFind

Find a Doctor

Matthias Bolz

Kepler University Hospital
Male

Bio


Matthias Bolz is in Linz, Austria. They have been an author on 70 peer reviewed articles in the past 15 years. Dr. Bolz's top three areas of expertise are Diabetic Retinopathy, Age-Related Macular Degeneration, and Late-Onset Retinal Degeneration.

Contact

Linz, AT

Latest Research


Latest Advance
Study
  • Condition: Diabetic Macular Edema
  • Journal: Acta ophthalmologica
  • Treatment Used: Intravitreal Ranibizumab or Dexamethasone Implant
  • Number of Patients: 18
  • Published —
This study determined the effect of intravitreal ranibizumab and a dexamethasone implant on aqueous humour cytokine, protein and enzyme levels and correlated findings to morphologic and functional changes.
Latest Advance
Study
  • Condition: Age-related Maculopathy
  • Journal: The British journal of ophthalmology
  • Treatment Used: Three Intravitreal Injections of Aflibercept (IVA)
  • Number of Patients: 20
  • Published —
This study investigated changes in ocular perfusion following three consecutive intravitreal injections with aflibercept for treatment of neovascular age-related macular degeneration (nAMD).
Latest Advance
Study
  • Condition: Age-Related Maculopathy
  • Journal: Acta ophthalmologica
  • Treatment Used: Intravitreal Injection Of Aflibercept
  • Number of Patients: 20
  • Published —
This study evaluated if the application of aflibercept (medicine that inhibit formation of new blood vessels) could induce alterations in ocular perfusion (blood supply in the eyes) in patients with age-related maculopathy (degenerative eye disease causing vision loss).

Clinical Trials


This doctor has not participated in any recent clinical trials.

All Publications
View All


Publication
Study
  • Journal: Klinische Monatsblatter fur Augenheilkunde
  • Published —
Correction: Safety, Efficacy and Protective Aspects of an Add-on Paracentesis during Intravitreal Injections

Contact

Linz, AT

Insurance

Contact them to find out if they accept your insurance plan.